Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
IPO Year: 2015
Exchange: NYSE
Website: glaukos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2025 | $86.00 | Overweight → Equal Weight | Wells Fargo |
| 2/19/2025 | $140.00 → $200.00 | Neutral → Outperform | Mizuho |
| 12/11/2024 | $132.00 → $162.00 | Neutral → Buy | Citigroup |
| 12/6/2024 | $182.00 | Buy | UBS |
| 12/2/2024 | $120.00 | Equal-Weight → Underweight | Morgan Stanley |
| 7/10/2024 | $132.00 | Buy → Neutral | Citigroup |
| 5/6/2024 | $84.00 → $125.00 | Hold → Buy | Jefferies |
| 12/21/2023 | $66.00 → $91.00 | Neutral → Overweight | JP Morgan |
| 12/4/2023 | $65.00 | Equal-Weight | Morgan Stanley |
| 11/28/2023 | $88.00 | Buy | Truist |
10-Q - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
DEFA14A - GLAUKOS Corp (0001192448) (Filer)
DEF 14A - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
SCHEDULE 13G/A - GLAUKOS Corp (0001192448) (Subject)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (Int
Industry Leaders Partner to Advance Vision Testing and Digital Solutions to Expand Patient Access to Eye Care Globally Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE:GKOS) announced a new collaboration and the launch of RadiusXR's new wearable vision testing platform - Inspire®. This collaboration unites RadiusXR's innovative visual field platform and Topcon Healthcare's global leadership in robotic diagnostics and digital healthcare solutions with Glaukos' commitment to expanding patient access by democratizing the diagnosis of ophthalmic diseases such as glaucoma. Together, the companies aim to expand access and enable doctors to provide visual field exams and education
PDUFA Date Set for October 20, 2025 Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the "Day 74" notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA's review
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, including: In a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials, iDose TR (travoprost intracameral implant) 75 mcg, an FDA-approved prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma, demonstrated sustained substantial IOP reductions as approximately 70% of iDose TR subj
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal disease. "The NDA submission for Epioxa represents an important milestone for our company as it brings us one step closer in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive co
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel the
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY Stephens Annual Investment Conference on Wednesday, November 20, 2024, at 10:00 a.m. ET in Nashville, TN BTIG Ophthalmology Day on Monday, December 2, 2024, at 4:40 p.m. ET (Virtual) Piper Sandler Annual Healthcare Conference on Wednesday, December 4, 2024, at 1:00 p.m. ET in New York City
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis
Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form
Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (Int
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2024. Key highlights for the third quarter of 2024 include: Record net sales of $96.7 million increased 24% year-over-year. Glaucoma record net sales of $76.0 million increased 30% year-over-year. Corneal Health net sales of $20.6 million increased 5% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately 82%. Raised 2024 net sales guidance to $377 million to $379 million, compared
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 4, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (In
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2024. Key highlights include: Record net sales of $95.7 million in Q2 2024 increased 19% year-over-year on a reported basis and 20% year-over-year on a constant currency basis. Glaucoma record net sales of $75.9 million in Q2 2024 increased 23% year-over-year. Corneal Health net sales of $19.8 million in Q2 2024 increased 7% year-over-year. Gross margin of approximately 76% and non-GAAP gross margin of approximately 82%
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 financial results after the market close on Wednesday, July 31, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 31, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (In
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. Corneal Health net sales of $18.4 million in Q1 2024 increased 4% year-over-year. Gross margin of approximately 76% and non-GAAP gross margin of approximately 83% in Q1 2024. Raised 2024 net sales guidance to $357 to $365 million, c
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 1, 2024. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (Interna
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00
Mizuho upgraded Glaukos from Neutral to Outperform and set a new price target of $200.00 from $140.00 previously
Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $162.00 from $132.00 previously
UBS initiated coverage of Glaukos with a rating of Buy and set a new price target of $182.00
Morgan Stanley downgraded Glaukos from Equal-Weight to Underweight and set a new price target of $120.00
Citigroup downgraded Glaukos from Buy to Neutral and set a new price target of $132.00
Jefferies upgraded Glaukos from Hold to Buy and set a new price target of $125.00 from $84.00 previously
JP Morgan upgraded Glaukos from Neutral to Overweight and set a new price target of $91.00 from $66.00 previously
Morgan Stanley initiated coverage of Glaukos with a rating of Equal-Weight and set a new price target of $65.00
Truist initiated coverage of Glaukos with a rating of Buy and set a new price target of $88.00